RxDoctor Payments Data

Syed Hamzavi, MD

MOHS-Micrographic Surgery · Clinton Twp, MINPI 1295780989

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (42.3%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Insmed, Inc. at 43.3% of the total. 2025 is the largest year on record at $2,104, 5.7 times the $368 reported in 2019.

$4,274in general payments, 2019–2025

Across 106 payments — averaging $40.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$2K
  • Incyte Corporation$728
  • AbbVie$420
  • Johnson & Johnson$215
  • Novartis$190
  • Kerecis Limited$142
  • plus $728 from 15 others
$5,698,255in research payments, 2019–2025

Across 853 payments — averaging $6680.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Incyte Corporation$4.3M
  • Janssen Research & Development, LLC$412K
  • E.r. Squibb & Sons, L.L.C.$164K
  • Nielsen Biosciences, Inc.$160K
  • Amgen$119K
  • Vanda Pharmaceuticals Inc.$109K
  • plus $476K from 11 others

What the payments were for

  • Consulting fees$68016%
  • Travel & lodging$1,65839%
  • Food & beverage$1,80742%
  • Education$1283%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,274 in reported general payments places this provider in the 70th percentile of 30 mohs-micrographic surgery providers in Michigan.

See all mohs-micrographic surgery providers in Michigan

Medicare billing

Part B allowed, 2024
$742,488
Medicare patients
2,024
Services billed
11,058

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab25$200,666
Dupixent PenDupilumab11$41,535
Fluorouracil68$4,006
Metronidazole26$3,014
Clobetasol Propionate61$2,438
Betamethasone Dipropionate38$1,721
Ketoconazole67$1,359
Ammonium Lactate45$796
Triamcinolone Acetonide91$784
Clindamycin Phosphate23$580
Hydrocortisone76$410
Imiquimod16$362
Cephalexin70$324
Fluocinonide17$310
Clotrimazole21$224

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Clinton Twp

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →